NASDAQ: RNA
Atrium Therapeutics Inc Stock Ownership - Who owns Atrium Therapeutics?

Insider buying vs selling

Have Atrium Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Sarah BoyceDirector2026-09-18126,418$8.95
$1.13MSell
W. Michael FlanaganDirector2026-09-1822,812$8.95
$204.17kSell
Kathleen P. GallagherCEO;Pres2026-09-1811,632$8.95
$104.11kSell
Rocio Martin HoyosCStrat2026-09-188,320$8.95
$74.46kSell
Steven George HughesMed2026-09-1821,459$8.95
$192.06kSell
Stephanie KenneyCXO2026-09-182,375$8.95
$21.26kSell
Brendan R. WinslowCFO2026-09-186,742$8.95
$60.34kSell
Husam YounisCSci2026-09-1811,216$8.95
$100.38kSell

1 of 1

RNA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RNA insiders and whales buy or sell their stock.

RNA Shareholders

What type of owners hold Atrium Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sarah Boyce0.81%138,668$1.09MInsider
Kathleen P. Gallagher0.70%119,729$938.68kInsider
Steven George Hughes0.30%51,638$404.84kInsider
Husam Younis0.24%41,441$324.90kInsider
Rocio Martin Hoyos0.22%38,340$300.59kInsider
Brendan R. Winslow0.22%36,859$288.97kInsider
Stephanie Kenney0.19%33,085$259.39kInsider
W. Michael Flanagan0.19%31,974$250.68kInsider
Troy Edward Wilson0.07%11,731$91.97kInsider
Carsten Boess0.06%11,005$86.28kInsider

1 of 3

RNA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNA0.08%3.04%Net SellingNet Selling
TLSA0.00%82.25%Net BuyingNet Buying
SPRB0.01%99.99%Net Selling
ARMP0.01%99.99%Net SellingNet Selling
CRBU0.05%8.03%Net Selling

Atrium Therapeutics Stock Ownership FAQ

Who owns Atrium Therapeutics?

Atrium Therapeutics (NASDAQ: RNA) is owned by 0.08% institutional shareholders, 3.04% Atrium Therapeutics insiders, and 96.87% retail investors. Sarah Boyce is the largest individual Atrium Therapeutics shareholder, owning 138,668.00 shares representing 0.81% of the company. Sarah Boyce's Atrium Therapeutics shares are currently valued at $1.09M.

If you're new to stock investing, here's how to buy Atrium Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.